weight loss drugs News
Latest articles and news about weight loss drugs on AXL Media.
Latest Articles
- New Research Reveals Sharp Social Stigma and "Effort Bias" Against Patients Using GLP-1 Weight Loss Drugs
Published: Apr 24, 2026
Section: Mental Health
A multi-national study published in Scientific Reports indicates that individuals who use anti-obesity medications are judged as having less moral character and being less deservin...
- A Potential Catalyst in Eli Lilly’s 150-Year History
Published: Apr 18, 2026
Section: Companies & Industry
Eli Lilly, a titan in the pharmaceutical industry for a century and a half, is navigating a pivotal moment with the recent launch of Foundayo, an oral GLP-1 treatment. The company,...
- AI Analysis of 400,000 Reddit Posts Identifies Unreported Side Effects Linked to Popular GLP-1 Weight-Loss Drugs
Published: Apr 10, 2026
Section: Medical News
University of Pennsylvania researchers utilized large language models to scan over half a decade of social media discussions regarding semaglutide and tirzepatide. The study uncove...
- Clinical Study Warns of Critically Low Protein Intake and Nutritional Risks for GLP-1 Drug Users
Published: Apr 10, 2026
Section: Medical News
A real-world analysis of adults using GLP-1 receptor agonists, such as semaglutide and tirzepatide, has identified a significant risk of nutritional deficiency due to drastically r...
- Clinical Case Study Reveals Semaglutide Treatment Linked to Near Total Cessation of Alcohol Consumption
Published: Apr 3, 2026
Section: Medical News
A 34-year-old male treated with semaglutide for class 2 obesity experienced a dramatic reduction in alcohol dependency, with his intake dropping from 15 drinks weekly to nearly zer...
- Food Giants and Restaurants Pivot Menus as GLP-1 Adoption Reshapes American Caloric Consumption Patterns
Published: Apr 2, 2026
Section: Companies & Industry
The rapid rise of GLP-1 weight-loss medications is forcing a structural shift in the food and beverage industry, with one in eight U.S. adults now utilizing these treatments. Major...
- Danone Secures 1 Billion Euro Acquisition of Huel to Capitalize on Global Health Nutrition Demand
Published: Apr 2, 2026
Section: Mergers & Acquisitions
French food conglomerate Danone has reached an agreement to acquire the British meal replacement specialist Huel to bolster its presence in the rapidly expanding nutritionally comp...
- UK Drug Watchdog Backs Novo Nordisk's Wegovy for Heart Disease Prevention via NHS
Published: Apr 1, 2026
Section: Companies & Industry
The National Institute for Health and Care Excellence (NICE) has recommended Wegovy for reducing the risk of heart attacks and strokes in obese adults. This landmark decision allow...
- Medical Experts Warn GLP-1 Weight Loss Drugs Require Lifestyle Integration to Ensure Long-Term Health Success
Published: Mar 26, 2026
Section: Medical News
As GLP-1 medications like Ozempic surge in popularity, physicians emphasize that appetite suppression alone is insufficient for sustainable health improvements. Clinical reports in...
- Abrupt Discontinuation of GLP-1 Medications Erases Life-Saving Cardiovascular Benefits According to WashU Study
Published: Mar 18, 2026
Section: Research
A massive study of over 333,000 U.S. veterans reveals that stopping GLP-1 drugs like semaglutide and tirzepatide leads to a rapid resurgence in the risk of heart attack, stroke, an...
- Study Finds Preterm Birth Risk Linked to Underlying Diabetes Rather Than Inadvertent GLP-1 Weight Loss Drug Exposure
Published: Mar 18, 2026
Section: Health
A massive Danish study of over 750,000 pregnancies has determined that while weight-loss drugs like Ozempic are associated with a higher risk of premature birth, the danger appears...
- High-Dose Wegovy Linked to Significantly Higher Risk of Sudden Sight Loss and "Eye Stroke" Compared to Other Semaglutide Medications
Published: Mar 12, 2026
Section: Research
A new analysis of FDA adverse event reports published in the British Journal of Ophthalmology reveals that the weight-loss drug Wegovy is associated with a five-fold higher risk of...